FDA Pharmacogenomic Regulation: Three Guidances, Fall Workshop
Executive Summary
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
You may also be interested in...
FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit
Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)
FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit
Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)
Pharmacogenomics Moves Into Spotlight With Completion Of Genome Project
Industry is ready to "embrace" pharmacogenomic-based drug development as long as commercial and regulatory applications are based on a full understanding of the technology, AstraZeneca VP-Clinical Development Glenn Gormley, MD/PhD, said during FDA's risk management public workshop April 9